The Peter Attia Drive

Snapshot · The Peter Attia Drive

#403 ‒ Peptides: separating scientific promise from marketing hype

Explore episode Aug 10, 2026

Where this was said

Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented

At 43:40 · chapter starts 43:00

The episode's most structurally contrarian argument arrives here: the popular claim that pharmaceutical companies ignore effective natural peptides because they can't be patented. Peter grants the kernel of truth — you can't patent a product of nature in raw form — but then systematically dismantles the larger claim. Companies routinely patent modified analogs, new salts, conjugates, delivery systems, manufacturing processes, and dosing regimens. Rapamycin, metformin, and the statins all began as natural molecules and became commercially patentable. Even BPC-157 has existing patents on its salts and production methods. More powerfully, Peter notes that if gray-market peptides truly worked as advertised, the same pharmaceutical industry currently racing to develop GLP-1 variants would be racing to develop them too. The conspicuous absence of that race is telling. Many gray-market wellness peptides are in fact drugs that originated inside the pharmaceutical pipeline and were abandoned — not suppressed, but abandoned — due to inadequate efficacy, safety concerns, poor pharmacokinetics, or competition from better drugs. The CJC-1295 / tesamorelin comparison makes this concrete: same biology, developed simultaneously, but tesamorelin's superior data got it over the finish line while CJC-1295 was dropped. The gray market, Peter concludes, is pharma's salvage yard.

Business
The Patent Myth: Pharma Would Race to Develop Peptides If They Worked

#403 ‒ Peptides: separating scientific promise from marketi… · Aug 10, 2026 Business

You can't patent a product of nature, but companies routinely patent modified analogs, salts, delivery systems, and dosing regimens. Rapamycin, metformin, and the statins all started as natural molecules and became patentable. If gray-market peptides delivered on their claims, the same industry racing to develop GLP-1 variants would already be racing to develop them.

Similar snapshots

Health & Fitness
Pipe broke → hydrogen sulfide studio air

Tortilla Face · Aug 10, 2026

A broken pipe filled the Bad Friends studio with what the hosts identified as hydrogen sulfide — microscopic fecal aeroparticles — that the crew denied smelling.